78
Participants
Start Date
April 3, 2017
Primary Completion Date
December 29, 2022
Study Completion Date
December 29, 2022
Ixabepilone
"Ixabepilone will be administered at 20 mg/m2 intravenously days 1, 8, 15 of a 28-day cycle over one hour.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response"
Bevacizumab
"Bevacizumab will be administered at 10 mg/kg intravenously days 1, 15 of a 28-day cycle over one hour. Bevacizumab will be infused after ixabepilone. The first dose of bevacizumab will be administered intravenously over 90 minutes; the second dose may be administered over 60 minutes if no prior reaction to previous infusion; subsequent doses may be administered over 30 minutes if no prior reaction to previous infusion.~Treatment will continue until progression, death, or prohibitive side effects. If any patient has a complete response, patient may stop treatment after 2 additional consolidation cycles following documented complete response."
Marlene & Stewart Greenebaum Comprehensive Cancer Center, University of Maryland, Baltimore
Smilow Cancer Hospital at Yale New Haven, New Haven
R-Pharm US LLC.
INDUSTRY
Yale University
OTHER